Clay Mineral–Vactosertib Complex for pH-Triggered Bowel Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing compounds like vactosertib face challenges with inconsistent internal resorption and limited absorption in the lower digestive tract due to pH-dependent charge and solubility variations, leading to rapid absorption in the upper digestive tract and short half-life, making long-term pharmacological effects difficult to achieve.
Innovation Solution
A pharmaceutical composition is developed comprising a complex of vactosertib or its pharmaceutically acceptable salt with a clay mineral, specifically bentonite, which adsorbs the compound at low pH and releases it at higher pH, allowing controlled delivery to the bowel for sustained action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If the compound is administered orally, then it is rapidly absorbed in the upper digestive tract, but the internal resorption is not constant and the half-life is short
Solution Approach 1:
A clay mineral complex acts as an intermediary carrier between the compound and the lower digestive tract. The complex adsorbs the compound in the upper digestive tract and releases it in the lower digestive tract, serving as a mediator that controls the timing and location of drug release to achieve consistent internal resorption.
Solution Approach 2:
The patent utilizes pH-dependent parameter changes to control drug release. The clay mineral complex releases the compound when the pH changes from acidic (upper digestive tract) to neutral/alkaline (lower digestive tract), thereby controlling the release timing based on environmental parameter changes to achieve consistent absorption.
2Quantity of substance
If the compound is rapidly absorbed in the upper digestive tract, then bioavailability is increased, but the action duration is limited due to short half-life
Solution Approach 1:
The clay mineral complex performs preliminary adsorption of the compound in the upper digestive tract, preserving the compound until the lower digestive tract is reached. This preliminary action extends the time the compound remains in the system, thereby extending the action duration while maintaining bioavailability.
Solution Approach 2:
The complex ensures continuous delivery of the compound to the lower digestive tract over an extended period. Instead of rapid single-pulse absorption, the complex provides sustained release, maintaining useful action throughout the digestive process and extending the overall action duration.
3Reliability
If the compound is delivered to the bowel, then treatment efficacy is improved, but the delivery is not targeted due to pH-dependent charge variations
Solution Approach 1:
The patent applies local quality by making the delivery system responsive to local pH conditions. The clay mineral complex is designed to release the compound specifically in the lower digestive tract where the pH is neutral to alkaline, creating a localized release zone that matches the target treatment area.
Solution Approach 2:
The system utilizes pH parameter changes as a triggering mechanism for targeted delivery. The compound is released when the pH changes from acidic to neutral/alkaline environments, which naturally occurs when moving from the upper to lower digestive tract, thereby achieving targeted delivery based on environmental parameter changes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The clay mineral/vactosertib complex ensures stable delivery and prolonged action in the bowel, with improved absorption in the small intestine and targeted release in the large intestine, enhancing treatment efficacy for inflammatory bowel disease.
Implementation Method 1
a complex of a compound of Chemical Formula 1 or a pharmaceutically acceptable salt thereof; and a clay mineral... preparing a complex by mixing a solution containing a compound of Chemical Formula 1 or a pharmaceutically acceptable salt thereof, an acidic reaction solution, and a clay mineral suspension to adsorb the compound onto the clay mineral
Data Source
AI summary
The present invention relates to a pharmaceutical composition for prevention, alleviation, and treatment of inflammatory bowel disease, the composition comprising a complex of a compound of Chemical Formula 1 or a pharmaceutically acceptable salt thereof and a clay mineral; a method for prevention, alleviation, and treatment of inflammatory bowel disease by using same; and a preparation method of the pharmaceutical composition.